methylprednisolone has been researched along with lamivudine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Esquivel, CO; Garcia, G; Imperial, JC; Keeffe, EB; Monge, H; So, SK | 1 |
| Chen, CH; Cheng, CH; Lee, WC; Lian, JD; Shu, KH; Wu, MJ | 1 |
| Bielefeld, P; Cohen, P; Guillevin, L; Hausfater, P; Imbert, B; Larroche, C; Loustaud-Ratti, V; Mahr, A; Petitjean, P; Queyrel, V; Roudier, J; Smadja, D | 1 |
| Yoshiba, M | 1 |
| Bernard, M; Bouhour, D; Boulliat, J; Fleury, J; Laurent-Coriat, C; Tilikete, C; Vighetto, A | 1 |
| Barbaria, F; De Lisi, S; Di Marco, V; Li Vecchi, M; Maringhini, S | 1 |
| Chizzolini, C; Landis, T; Perren, F; Pot, C; Ribi, C; Tiercy, JM; Vokatch, N | 1 |
| Auguet, T; Barragan, P; Quer, JC; Ramírez, R; Richart, C; Sirvent, JJ | 1 |
| Jiang, ZP; Zhou, TB | 1 |
| Balbir-Gurman, A; Braun, M; Braun-Moscovici, Y; Markovits, D; Nahir, MA; Saadi, T | 1 |
| Arai, M; Fujiwara, K; Haga, Y; Kanda, T; Kato, N; Nakamura, M; Oda, S; Yasui, S; Yokosuka, O; Yonemitsu, Y | 1 |
| Jiang, F; Liu, H; Xing, X; Zhang, M; Zheng, K; Zhou, C | 1 |
2 review(s) available for methylprednisolone and lamivudine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Recent advances in the treatment of fulminant hepatitis B].
Topics: Acute Disease; Antiviral Agents; Carrier State; Cyclosporine; Drug Therapy, Combination; Guanine; Hemodiafiltration; Hepatitis B; Humans; Immunosuppressive Agents; Lamivudine; Liver Failure, Acute; Liver Transplantation; Methylprednisolone; Plasma Exchange; Prognosis; Pulse Therapy, Drug | 2004 |
2 trial(s) available for methylprednisolone and lamivudine
| Article | Year |
|---|---|
Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
Topics: Adolescent; Adult; Alanine Transaminase; Anti-Inflammatory Agents; Antilymphocyte Serum; Bilirubin; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Kidney Transplantation; Lamivudine; Liver Failure; Male; Methylprednisolone; Middle Aged; Prothrombin Time; Treatment Outcome; Virus Activation | 2001 |
Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Drug Administration Schedule; Female; Hepatitis B; Humans; Lamivudine; Male; Methylprednisolone; Plasma Exchange; Polyarteritis Nodosa; Prednisone; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
16 other study(ies) available for methylprednisolone and lamivudine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?
Topics: Adolescent; Adult; Asian People; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B e Antigens; Humans; Immunization, Passive; Immunoglobulins; Immunosuppression Therapy; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Methylprednisolone; Middle Aged; Recurrence; Reverse Transcriptase Inhibitors; Survival Rate | 1999 |
[HIV infection presenting with bilateral optic neuropathy].
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Disease Progression; Drug Therapy, Combination; Evoked Potentials, Visual; Facial Nerve Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ischemia; Lamivudine; Lopinavir; Male; Meningitis, Viral; Methylprednisolone; Middle Aged; Optic Disk; Optic Nerve Diseases; Polyradiculopathy; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Visual Fields; Zidovudine | 2006 |
Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Follow-Up Studies; Glomerulonephritis; Glucocorticoids; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Humans; Hypertension; Kidney Glomerulus; Kidney Tubules, Proximal; Lamivudine; Methylprednisolone; Prednisone; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2006 |
Combined antiviral-immunosuppressive treatment in human T-lymphotrophic virus 1-Sjögren-associated myelopathy.
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Female; HTLV-I Infections; Humans; Immunosuppressive Agents; Lamivudine; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Organophosphonates; Prednisone; Radiography; Sjogren's Syndrome; Tenofovir | 2006 |
Lamivudine in the treatment of hepatitis B virus-related polyarteritis nodosa.
Topics: Anti-HIV Agents; Cyclophosphamide; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Methylprednisolone; Middle Aged; Polyarteritis Nodosa | 2007 |
Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report.
Topics: Adult; Antiviral Agents; Biopsy; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Kidney Function Tests; Kidney Glomerulus; Lamivudine; Male; Methylprednisolone; Nephrosis, Lipoid; Telbivudine; Thymidine; Treatment Outcome | 2015 |
Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Alanine Transaminase; Antirheumatic Agents; Azathioprine; Cyclophosphamide; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Infliximab; Lamivudine; Male; Methylprednisolone; Middle Aged; Pilot Projects; Rheumatic Diseases | 2016 |
Early Combination Therapy with Corticosteroid and Nucleoside Analogue Induces Rapid Resolution of Inflammation in Acute Liver Failure due to Transient Hepatitis B Virus Infection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Guanine; Hepatitis B; Hepatitis B virus; Humans; Inflammation; Lamivudine; Liver Failure, Acute; Male; Methylprednisolone; Middle Aged; Prednisolone; Retrospective Studies; Survival Rate; Time-to-Treatment | 2018 |
Clinical Effect of Lamivudine Combined with Leflunomide and Methylprednisolone Tablets in the Treatment of Hepatitis B Virus-Associated Glomerulonephritis and Its Influence on Renal Function Indicators.
Topics: Glomerulonephritis; Hepatitis B virus; Humans; Interleukin-4; Kidney; Lamivudine; Leflunomide; Methylprednisolone; Retrospective Studies; Tablets | 2023 |